Cure8 news brief
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
Patients and clinicians following new treatment options or clinical trials may find the comparative efficacy and subgroup results relevant.
Adult patients with ulcerative colitis or Crohn’s disease interested in emerging therapies or clinical trials, clinicians treating IBD, researchers tracking TL1A programs, and patients on advanced biologic therapies monitoring new options.
Sanofi and Teva published phase 2 data for duvakitug (an anti‑TL1A antibody) in ulcerative colitis and Crohn’s disease and presented updated subgroup and secondary endpoint results at the ECCO meeting.
The readout reported endoscopic improvement rates at 14 weeks for low and high doses (45% and 50%) versus 23% for placebo, and discussed placebo‑adjusted deltas compared to rival TL1A programs from Roche (Roivant) and Merck (Prometheus). The companies said the results are informing phase 3 design decisions.
Duvakitug’s phase 2 data included analyses by prior advanced‑therapy exposure (naïve vs experienced) and endoscopic outcomes; Sanofi/Teva reported higher placebo‑adjusted effects in some advanced‑therapy–experienced subgroups. The partners are finalizing a phase 3 plan informed by modeling from this study.
This is industry coverage focused on comparative clinical data and commercial prospects rather than new clinical guidance. It summarizes company‑reported trial outcomes and analysts’ commercial forecasts without presenting full study methods or patient‑level data.
This is a press/industry report summarizing company‑presented phase 2 results and analyst commentary. It does not provide full trial protocols, safety details, or peer‑reviewed publication. No immediate changes to clinical care are implied; phase 3 trials are planned to test efficacy and safety more definitively.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
